Washington University School of Medicine
St Louis, Missouri, 63110, United States
NCT Number: NCT05202743
This study is designed to be a pragmatic, single-arm trial to evaluate the efficacy, implementation, and feasibility of an online ALS-specific self-compassion training program to enhance self-compassion and improve quality of life.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
St Louis, Missouri, 63110, United States
Optimizing quality of life for people with ALS is a primary goal of ALS multidisciplinary care, Therefore, it is especially important to conduct research into interventions to address the psychological needs and well-being of people with ALS.
Recent studies have shown that mindfulness-based interventions promote improved quality of life for people with ALS. It is essential that such strategies as mindfulness-based interventions consider the specific needs of the ALS population and potential barriers to participation.
Very few studies have evaluated mindfulness-based interventions in the ALS population and no studies to date have evaluated self-compassion people with ALS. Self-compassion has been linked to increased emotional resilience, psychological well-being, and quality of life in multiple populations.
The intervention will include a 2-part workshop entitled 'Introduction to Mindful Self-Compassion for Persons Living with Amyotrophic Lateral Sclerosis.' Experience and feedback gained from the workshop will be incorporated into the format for an 8-week course in Cultivating Self-Compassion for persons living with ALS (Compassion pALS). Compassion pALS will be adapted from the Mindful Self-Compassion (MSC) Program to accommodate ALS clinical features and limit potential barriers to participation.
The primary outcome will be quality of life assessed with the Amyotrophic Lateral Sclerosis Assessment Questionnaire 5 (ALSA-5). Participants will be assessed at the 2-part workshop (T0, baseline), start of the 8 week Compassion pALS course (T1 = pre-intervention); after completing the intervention (T2, post-intervention). Secondary outcomes will include Secondary outcome measures the Self-Compassion Scale Short Form (SCS-SF), Patient Health Questionnaire-9 (PHQ-9), General Anxiety Disorder-7 (GAD-7), Amyotrophic Lateral Sclerosis Functional Rating Scale-R (ALSFRS-R), Feasibility of Intervention Measure (FIM), Acceptability of Intervention Measure (AIM), and Intervention Appropriateness Measure (IAM).
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Open to ALS patients interested in mindfulness training.
Time frame: Baseline (T1); post 8-week intervention (T2)
Amyotrophic Lateral Sclerosis Assessment Questionnaire 5 (ALSAQ-5; Jenkinson et al., 2001.
Time frame: Baseline (T1); post 8-week intervention (T2)
Self-Compassion Scale Short Form (SCS-SF; Raes et al., 2011)
Time frame: Baseline (T1); post 8-week intervention (T2)
Self-Administered ALS Functional Rating Scale-Revised (SA-ALSFRS; Montes et al., 2006)
Time frame: Baseline (T1); post 8-week intervention (T2)
General Anxiety Disorder-7 (GAD-7; Spitzer et al., 2006)
Time frame: Baseline (T1); post 8-week intervention (T2)
Patient Health Questionnaire-9 (PHQ-9; Kroenke et al., 2002)
Time frame: Baseline (T1); post 8-week intervention (T2)
Feasibility of Intervention Measure (FIM; Weiner et al., 2017)
Time frame: Baseline (T1); post 8-week intervention (T2)
Acceptability of Intervention Measure (AIM; Weiner et al., 2017)
Time frame: Baseline (T1); post 8-week intervention (T2)
Intervention Appropriateness Measure (IAM; Weiner et al., 2017)
Washington University School of Medicine
Other
Cultivating Self-Compassion Course for Persons Living With Amyotrophic Lateral Sclerosis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01925196
Amyotrophic Lateral Sclerosis, Brain Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT05562960
Amyotrophic Lateral Sclerosis, Central Nervous System Diseases
Taipei, Taiwan
View Trial DetailsNCT04259255
ALS, Amyotrophic Lateral Sclerosis
Phoenix, Arizona, United States
View Trial DetailsNCT05189106
Alzheimer Disease, Amyotrophic Lateral Sclerosis
Boston, Massachusetts, United States
View Trial Details